A New Federal Framework for Autism
The 2026 to 2028 IACC Draft Strategic Plan reflects a remarkable shift toward many of the medical and scientific questions explored in A Blind Spot on Autism.
This working draft represents a major shift in how autism may be studied, understood, and addressed.
The Interagency Autism Coordinating Committee (IACC) has released a working draft of its Strategic Plan for 2026 to 2028. For families who have spent years being told that medical symptoms were simply “part of autism,” the draft reads differently than what has come before.
Below is AIDA's summary of what the draft plan says and why it matters.
Autism is more than a behavioral diagnosis
The new federal draft treats autism as a lifelong condition involving multiple biological systems. It prioritizes research and clinical care involving:
The focus is expanding from managing behaviors to understanding health, function, and biology.
There is not just one autism
The plan makes heterogeneity its organizing principle. It says autism may involve different combinations of:
What causes autism?
Which mechanisms matter in which individuals?
The draft describes autism as arising through multiple interacting pathways, rather than one universal cause.
Regression is now a national priority
The draft estimates that neurodevelopmental regression occurs in 30 to 40% of autistic children.
Loss of language, motor skills, adaptive function, sleep stability, or engagement should not automatically be dismissed as part of autism.
The plan calls for:
- A standardized definition of regression
- Rapid medical evaluation
- Prospective research cohorts
- Serial biospecimens
- Biomarker development
- Subgroup-specific treatment trials
It proposes a National Neurodevelopmental Regression Initiative to build the infrastructure needed to detect, understand, and treat regression in autism.
Sudden deterioration requires medical investigation
The plan warns against diagnostic overshadowing. Abrupt regression, OCD symptoms, restrictive eating, aggression, self-injury, sleep collapse, movement changes, seizures, or personality change may have:
- Presume that every change is caused by autism.
- Presume that every change is immune-mediated.
Investigate.
Appropriate clinical history, presentation, laboratory testing, and examination is needed to uncover treatable causes of sudden deterioration.
Maternal health is part of the investigation
The strategic plan identifies research priorities that include maternal health and early developmental exposures.
Research priorities include:
- Maternal immune activation
- Placental biology
- Infection during pregnancy
- Medications
- Diet and nutritional status
- Developmental timing and exposures
Research into maternal health, placental biology, developmental timing, and fetal susceptibility may influence later outcomes.
Federal research is shifting beyond genetics
The draft plan moves federal autism research away from a primarily genetic focus and toward immune, metabolic, microbial, and environmental mechanisms — investigated alongside genetics rather than after it.
The starting point: FY 2025 NIH autism causation funding
Where the new plan invests: a more balanced portfolio, expanding investigation into:
Turning discovery into real-world impact
The proposed National Autism Precision Therapeutics Initiative (NAPTI) creates a clear path from research to patient benefit.
Discovery
Identify biological mechanisms and candidate targets.
Validation
Harmonize assays and confirm biomarkers.
Subgroup definition
Define biologically distinct subgroups of patients.
Precision trials
Conduct adaptive, multicenter trials by subgroup.
Implementation & outcomes
Move validated findings into care and measure real-world impact.
The right treatment for the right patient at the right time. Biology-driven research. Subgroup-specific care. Better outcomes across the lifespan.
Coordinated federal action is essential
The plan calls for federal agencies to work together to move research into clinical care.
FDA
NIH + FDA
Lead biomarker research, patient subgrouping, and precision trials.
HRSA
CDC + HRSA
Identify patterns, strengthen surveillance, and educate clinicians.
AHRQ
CMS + AHRQ
Improve access, diagnostic pathways, and standards of care.
DoD + federal partners
Expand research, resources, and support across the lifespan.
This page summarizes AIDA's review of the IACC Draft Strategic Plan for 2026–2028, a working draft. The public review and discussion date has been postponed and a new date is to be announced, expected September 2026. Descriptions on this page characterize the contents of that draft and are not federal policy. The full review is available as a PDF. Further reading is collected in the AIDA Research Library.